Anzeige
Mehr »
Mittwoch, 04.03.2026 - Börsentäglich über 12.000 News
60.000 USD pro Tonne! Entsteht hier der nächste Gewinner im Antimon-Boom?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
63 Leser
Artikel bewerten:
(0)

Micromedex CareNotes Available Within the MEDITECH Health Care Information System

ANN ARBOR, Mich., Jan. 19 /PRNewswire/ -- Thomson Reuters and MEDITECH have collaborated to offer content from the Micromedex CareNotes® System integrated within four applications of the MEDITECH Health Care Information System (HCIS) -- Emergency Department Management, Physician Care Manager, Oncology, and Patient Care System.

Hospitals use CareNotes, one of the Micromedex clinical evidence solutions from Thomson Reuters, to provide patients with educational information about all aspects of their care and health.

MEDITECH customers can now access CareNotes content within their workflow, streamlining the process of finding, delivering, and documenting personalized and relevant patient education in the hospital.

This solution meets the criteria defined by the Certification Committee for Healthcare Information Technology requiring hospital information systems to generate education material for medications, diagnosis, procedures, and tests that is tailored for the patient.

The new offering combines solid integration technology with the most trusted patient education content available to help clinicians provide patients with evidence-based, understandable, and accurate materials about their conditions, medications, treatments, post-discharge activities, and ongoing care.

MEDITECH customers will be able to seamlessly connect clinicians directly to relevant Micromedex education content at any point in the care process. This enables physicians, nurses, and pharmacists to help their patients take a more active role in their recovery, all without disrupting their workflow.

"Integrating CareNotes into the MEDITECH system gives our customers direct access to a leading content suppliers' comprehensive patient education materials without leaving their clinical system or altering their workflow," said Hoda Sayed-Friel, vice president of marketing at MEDITECH. "This new offering allows our customers to meet strict patient education guidelines and establish an electronic audit trail, all while providing patients easy-to-understand information regarding every aspect of their care and health."

The Micromedex CareNotes System supports every step in the continuum of care. With topics including diet, exercise and disease prevention and a host of "how-to" documents, CareNotes empowers patients to actively participate in their care, all while meeting Joint Commission and OBRA '90 patient education guidelines.

"Access to fully integrated patient education materials from within the hospital information system is increasingly important," said Thomas Hegelund, executive vice president for the Healthcare & Science business of Thomson Reuters. "MEDITECH customers can now have the highest quality education materials for their patients, readily accessible by clinicians from within their clinical workflow."

MEDITECH

MEDITECH has been the leader in the Health Care Information Systems (HCIS) industry since 1969. MEDITECH's applications unify clinical, administrative, and financial information across a health care organization, including acute care, long-term care, home health care, and physician practices. Today, more than 2,200 institutions worldwide use MEDITECH's information systems. For additional information on MEDITECH products and services, visit http://www.meditech.com/.

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto Stock Exchange (TSX: TRI) and New York Stock Exchange . For more information, go to http://www.thomsonreuters.com/.

Thomson Reuters

CONTACT: David Wilkins, +1-734-913-3397, david.wilkins@thomson.com

Web Site: http://www.thomsonreuters.com/

© 2010 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.